The Patent Finder

Idenix Pharmaceuticals, Inc.

27 patents currently held · Updated Nov 16, 2026
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 5 name spellings.

11
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 18, 2027
    The maintenance fee for 3′,5′-cyclic phosphoramidate prodrugs for HCV infection (US 9,109,001) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
  • 3 fees due May 17 to 24, 2027 · next May 17
  • 1 fee due Jul 26, 2027
    The maintenance fee for Compounds and pharmaceutical compositions for the treatment of viral infections (US 9,243,025) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
  • 1 fee due Sep 15, 2027
    The maintenance fee for Macrocyclic serine protease inhibitors (US 9,284,307) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,951,789Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
In force
 · High confidence
In forceHigh confidence
US 7,608,600Modified 2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections
In force
 · Medium confidence
In forceMedium confidence
US 7,902,202Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections
In force
 · High confidence
In forceHigh confidence
US 7,781,576Process for preparing a synthetic intermediate for preparation of branched nucleosides
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,932,240Phosphadiazine HCV polymerase inhibitors IV
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,093,379Macrocyclic serine protease inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,003,659Macrocyclic serine protease inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,993,595Macrocyclic Serine Protease Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 8,193,372Phosphothiophene and phosphothiazole HCV polymerase inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,362,0685,5-fused arylene or heteroarylene hepatitis C virus inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 27 patents shown.
Pro members see all 27.
Pro members: see all 27 patents
Also on record, not counted in the 27: 20 patents in force now held by others · 22 lapsed for an unpaid fee · 44 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

17 abandoned · 34 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited